公开(公告)号：EP2970443A4

公开(公告)日：2017-01-11

申请号：EP14770483

申请日：2014-03-14

申请人： GILL PARKASH S ,  LIU REN

发明人： GILL PARKASH S ,  LIU REN

IPC分类号： C07K16/00 ,  A61K39/00 ,  A61K39/395 ,  C12P21/08

CPC分类号： C07K16/28 ,  A61K47/48384 ,  A61K47/48569 ,  A61K47/48753 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6898 ,  A61K49/0032 ,  A61K49/0058 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/57492 ,  G01N2333/705

摘要： This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments.

摘要翻译： 此应用程序提供，除其他外，抗体或抗原结合片段，其靶向过度表达于肿瘤细胞，肿瘤内皮细胞和肿瘤启动癌细胞的细胞表面GRP78。 这些抗GRP78抗体，或其抗原结合片段，其具有用于GRP78具有高亲和力并且是免疫原性更低相比，在给定的物种及其未修饰的亲本抗体，E. G.，人，并且起抑制GRP78。 重要的是，本文新的分离的抗体和抗原结合片段，其减弱PI3K信号传导和促进肿瘤细胞凋亡，而对正常细胞不受影响。 的抗体和抗原结合片段可用于UPR-靶向癌症的治疗性处理是有用的。

公开(公告)号：EP2970443A2

公开(公告)日：2016-01-20

申请号：EP14770483.7

申请日：2014-03-14

申请人： Gill, Parkash, S. ,  Liu, Ren

发明人： Gill, Parkash, S. ,  Liu, Ren

IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6898 ,  A61K49/0032 ,  A61K49/0058 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/57492 ,  G01N2333/705

摘要： This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments.